Jumping translocation breakpoint (JTB) is a gene located on human chromosome 1 at q21 that suffers an unbalanced translocation in various types of cancers, and potentially encodes a transmembrane protein of unknown function. The results of cancer profiling indicated that its expression was suppressed in many cancers from different organs, implying a role in the neoplastic transformation of cells. Recently, we isolated JTB as a TGF-b1-inducible clone by differential screening. In this study, we characterized its product and biological functions. We found that it was processed at the N-terminus and located mostly in mitochondria. When expressed in cells, JTB-induced clustering of mitochondria around the nuclear periphery and swelling of each mitochondrion. In those mitochondria, membrane potential, as monitored with a JC-1 probe, was significantly reduced. Coinciding with these changes in mitochondria, JTB retarded the growth of the cells and conferred resistance to TGF-b1-induced apoptosis. These activities were dependent on the N-terminal processing and induced by wild-type JTB but not by a mutant resistant to cleavage. These findings raised the possibility that aberration of JTB in structure or expression induced neoplastic changes in cells through dysfunction of mitochondria leading to deregulated cell growth and/or death.
Introduction
Jumping translocation breakpoint (JTB) is a gene located on human chromosome 1 at q21 that is involved in translocation in many types of cancers. JTB was first identified as an open reading frame from the sequence near a fusion point at 1q21 translocated to telomeric repeats of acceptor telomeres in a case of jumping translocation and postulated to encode a protein of 16.4 kDa (Hatakeyama et al., 1999 ). An analysis of the protein structure revealed distinctive stretches in the Nand C-terminal regions (Hatakeyama et al., 1999) . The N-terminal stretch consisting of highly hydrophobic amino acids supposedly functions as a signal sequence for secretion of the polypeptide or for recruitment to membrane compartments, being processed and removed during the process. The other stretch in the C-terminal region is expected to constitute a transmembrane domain. Together, these characteristics suggested that JTB was a transmembrane protein.
Currently available cytogenetic evidence points to the importance of 1q21-q22 in tumor progression processes including the acquisition of drug resistance and ability to metastasize (Keung et al., 1998; Wong et al., 2003) and, thus, the functions of the genes located around the region are potentially associated with the processes, accounting for the frequent translocation of the region in many types of tumors. Alternatively, the possibility remains that the frequent translocation in this region is a simple reflection of chromosomal instability originating from a certain characteristic of the region such as a unique high-ordered structure of DNA. To distinguish between the two possibilities and evaluate the significance of the translocation, it is important to clarify the biological function of the gene products located around the translocation point. Previous studies reported on the possibility of an aberrant product and overexpression of JTB in a case of leukemia (Hatakeyama et al., 1999) and in hepatocellular carcinoma cases (Wong et al., 2003) , respectively. The study by Hatakeyama et al. (1999) of a case of leukemia showed that the jumping translocation resulted in the production of JTB devoid of the transmembrane and intracellular domains, and possibly secreted from cells. However, owing to a lack of knowledge on the biological function of JTB, the significance of the above change remains unclear.
In the present study, we characterized the JTB gene product and found that it was processed at its N-termina, largely localized to mitochondria in the cells, and had a profound effect on mitochondrial membrane potential, cell growth and cell death.
Results

Expression levels of JTB in normal and tumor tissues
During the course of studying the role of TGF-b1 in tumorigenesis, we isolated JTB as a TGF-b-inducible cDNA from NMuMG mouse mammary epithelial cells. Here, we validated this inducibility at the mRNA and protein levels as demonstrated in Figure 1a . Next, we compared expression levels of JTB mRNA between normal and cancerous tissues using a cancer-profiling array consisting of a tumor and a corresponding normal tissue sample from the same patient. The array was hybridized with a labeled JTB cDNA probe, and the results are shown in Figure 1b . The control array was hybridized with an ubiquitin cDNA. Among the tissues arrayed here, JTB expression was detected in the lung, kidney, stomach and colon, and importantly, when compared to normal samples, the expression levels decreased significantly in corresponding tumor samples in most, if not all, of the pairs.
Post-translational processing of JTB protein Expression vectors for JTB tagged with HA at its N-terminus or with Flag at its C terminus were Figure 1 Cancer-profiling array analysis of JTB mRNA expression. (a) NMuMG cells were treated with 2 ng/ml TGF-b1 for the periods indicated and analysed by real-time RT-PCR for quantification of mRNA or by Western blotting with the anti-JTB antibody for the protein. In the right panel, the intensity of the bands was measured using ImageJ, and fold-increase is shown at the bottom. Essentially, the same results were obtained in more than three independent experiments. (b) The cancer-profiling array containing 241 paired cDNA samples from 13 different tissue types was hybridized with the JTB open reading frame cDNA probe (upper panel) or with ubiquitin cDNA as a control (lower panel) according to the manufacturer's manual. Each pair of the array consists of a tumor sample (T) and a corresponding normal tissue sample (N) obtained from the same patient.
Characterization of JTB located in mitochondria T Kanome et al constructed, and the expressed proteins were examined by Western blotting with antibodies to the tags and JTB. As shown in Figure 2a , when the sample expressing HA-tagged JTB was analysed with the antibody to HA, a single band of around 20 kDa was detected corresponding to the size of full-length JTB (18 kDa) carrying the HA-tag (2.5 kDa) ( Figure 2a , lane 2). However, when the same sample was analysed with the antibody to JTB, which was raised against the C terminus of JTB, an additional smaller band of 17 kDa with much stronger intensity appeared (Figure 2a, lane 4) . Under some experimental conditions, the band appeared as a doublet, suggesting the presence of two cleavage sites ( Figure 2c, lane 7) . Importantly, the band of 17 kDa was undetectable with anti-HA antibody. The result suggested that the majority of JTB was post-translationally processed near the N-terminus to remove about a 3.5-kDa N-terminal polypeptide containing a 1-kDa end and the 2.5-kDa HA tag. If this is true, when the sample expressing the C-terminally Flag-tagged JTB is analysed, either of the antibodies to Flag tag and JTB would detect the N-terminally processed JTB protein with a molecular weight of around 18.5 kDa including the 1.5-kDa Flag tag at the C terminus as a major product. The data shown in Figure 2a , lanes 6 and 8, supported the hypothesis.
To substantiate the processing of JTB protein at its Nterminus and to identify the sites implicated in the cleavage, N-terminally HA-tagged expression vectors for JTB whose amino acids near the N-terminus were mutated, were constructed. In mutant 1, the 4th and 5th amino acids were changed from GA to DE, and in mutant 2, the 13th and 14th amino acids were changed from AG to DD as indicated in Figure 2b . The mutants were expressed in the cells and examined as above. Mutant 1 gave essentially the same result as wild-type JTB and produced one band of 20 kDa when blotted with the antibody to HA tag ( Figure 2c, lanes 2 and 3) , whereas two bands of 20 and 17 kDa were detected with anti-JTB antibody (Figure 2c, lanes 7 and 8) . In contrast, mutant 2 produced only the upper band of 20 kDa corresponding to the full-length protein, even when blotted with anti-JTB. Together, the observation suggested that the 20-kDa protein was a nascent fulllength form of JTB with the tag, and that it was cleaved near the N-terminal, in which the 13th or 14th amino acid was directly or indirectly involved. In most of the subsequent experiments, C-terminally Flag-tagged JTB was used in combination with either anti-Flag or anti-JTB antibodies to examine the behavior of the wild type, and mutant 2 was used as mutant JTB.
Subcellular localization of JTB
To determine the subcellular localization of JTB, we expressed the Flag-tagged JTB in NMuMG mouse mammary epithelial cells and stained the cells with antiFlag and anti-JTB antibodies. Microscopic observation suggested that wild-type JTB was localized to granular components around the nucleus, whereas the mutant JTB mainly distributed throughout the cytoplasm ( Figure 3A ). Co-staining with anti-Flag and anti-lamin B1 (a nuclear matrix marker), anti-calnexin (an endoplasmic reticulum marker), or anti-GM130 (a Golgi apparatus marker) antibodies suggested that neither form of JTB was mainly located in the compartments examined here except for a partial localization in the endoplasmic reticulum (data not shown).
We next investigated the mitochondrial localization of JTB by co-staining the cells expressing the wild-type JTB with anti-Flag antibody and a mitochondrial marker dye, Mito Tracker Red CM-H2TMROS. As demonstrated in Figure 3B , the stained patterns of antiFlag and Mito Tracker were almost identical in most cells, suggesting a mitochondrial localization of JTB. In addition, it was noticeable that expression of wild-type JTB, but not the mutant affected the distribution pattern of the mitochondria in the cells ( Figure 3B ). Whereas mitochondria existed as a tubular structure throughout the cytoplasm in untransfected cells (panel b), they appeared clustered around the nucleus in the cells expressing the wild-type JTB (panels e and h). In contrast, in most of the cells expressing the mutant JTB, mitochondria distributed more evenly in the cytoplasm as they did in the control cells (panel k).
We further examined the mitochondrial distribution of JTB through biochemical fractionation of the cells. The cells were disrupted, fractionated, and analysed by Western blotting with antibodies to JTB, calnexin, and the core I subunit of complex III in the mitochondrial (c) The proteins of the wild-and mutant-type JTB expressed in COS7 cells were examined by Western blotting using the anti-HA and anti-JTB antibodies. The expression vectors introduced into the cells were as follows: lanes 1 and 6, pCG-N-BL empty vector; lanes 2 and 7, HA-JTB for wild-type JTB; lanes 3 and 8, mutant 1; lanes 4, 5, 9 and 10, mutant 2. The rectangle highlights the absence of the processed forms in lanes 9 and 10.
Characterization of JTB located in mitochondria T Kanome et al respiratory chain (anti-OxPhos complex III). Although calnexin was distributed in microsomal fraction (E) as well as fraction M, JTB was exclusively detected in fraction M even with a longer exposure as was the core I subunit of complex III ( Figure 3C ). On the basis of the results of immunocytochemistry, we concluded that JTB was mostly distributed in mitochondria. In Figure 3D , the cells transfected with an empty vector or the wildtype JTB expression vector were disrupted, fractionated, and analysed by Western blotting with antibodies to JTB, demonstrating that exogenously expressed JTB was apparently distributed in the same pattern as the endogenous protein. Of note, most of the endogenous protein was present in the processed form. . At 24 h post-transfection, cells were disrupted and fractionated on a sucrose gradient as described in Materials and methods. The fractions containing equal amounts of protein were analysed by Western blotting using anti-JTB antibody. P1, nucleienriched fraction; S1, post-nuclear supernatant; S2, post-mitochondrial supernatant; C, cytoplasmic fraction. The arrowhead and arrow indicate the unprocessed and processed forms of JTB, respectively.
Characterization of JTB located in mitochondria T Kanome et al JTB affected morphology and membrane potential of mitochondria The localization of JTB in mitochondria prompted us to examine the effect of JTB on mitochondrial morphology and function. As mentioned above, a significant population of the cells expressing wild-type JTB showed an altered distribution of mitochondria clustered around the nucleus. Here, we observed thin sections of the cells by transmission electron microscopy to study the morphological change within individual mitochondria in detail. As shown in Figure 4a , most of the mitochondria in the cells expressing wild-type JTB were swollen or extended. Of interest, mitochondria maintained an apparently normal morphology in the cells expressing the mutant JTB, suggesting the need for the processing of JTB near its N-terminal for the effect on mitochondrial morphology. Next, the cells were incubated with JC-1, a membrane potential-sensitive probe for mitochondria. The control and the cells expressing the mutant JTB concentrated the dye in mitochondria into aggregates with red fluorescence, indicating a high potential of the mitochondrial membrane in those cells (Figure 4b , upper panels). In sharp contrast, in the cells expressing wildtype JTB, the formation of the red aggregates in mitochondria was markedly reduced, suggesting dissipation of the membrane potential in those mitochondria. This result suggested that the wild-type JTB affected the mitochondria to dissipate the inner membrane potential along with the induction of swelling.
Involvement of JTB in cellular growth and apoptosis
Because mitochondria are not only a source of cellular energy but also a key regulator of a diverse range of activities such as aerobic metabolism and apoptosis, it was likely that JTB, which was implicated in the regulation of mitochondrial membrane potential, eventually had an influence on cellular growth and/or death. Here we examined the growth rate by measuring the doubling time and incorporation of BrdU. Table 1 shows the doubling time using stable clones expressing the wild-type or mutant JTB, indicating that the expression of the wild-type JTB increased the doubling time by several hours compared with the control. The expression of the mutant affected doubling time only marginally. In Figure 5a , the incorporation of BrdU was measured after introducing expression vectors transiently into the cells. Consistent with the results of doubling time, the wild-type JTB but not the mutant inhibited BrdU incorporation to about 30% of the control (Figure 5a , left). Similar to NMuMG cells, wildtype JTB also suppressed the growth of human lung adenocarcinoma A549 cells (Figure 5a, right) . The expression levels of wild-type and mutant JTB were comparable as shown in Figure 5b . Under our culture conditions, about 4-9% of the population constantly underwent spontaneous cell death. However, the rate was not changed by the expression of JTB (Figure 6a , TGF-b (À); 24, 48 h), and thus, the suppression of growth observed here by wild-type JTB was unlikely owing to an increase in cell death.
In contrast to the overexpression of JTB, incorporation of BrdU was modestly increased, when the expression level of JTB was reduced to about 40% of the control using siRNA (Figure 5c ). From these results, we concluded that JTB was involved in growth control of the cells.
We also investigated the effect of JTB on cell death. In this study, we treated NMuMG cells with TGF-b1 which potently induced apoptosis in this cell line concurrently with the upregulation of JTB expression (Figure 1a ). Apoptotic cells were identified by the uptake of a dye into the cells, which occurred dependent on a disruption of the asymmetrical distribution of phosphatidylserine in the plasma membrane. Consistent with the increase in nonviable cells stained with trypan blue from around 10-30% (data not shown), the uptake of the dye was markedly increased by the treatment with TGF-b1 for 48 h (Figure 6a ). The expression of wildtype JTB suppressed the increase to 68% of the control, whereas that of the mutant JTB had only a marginal effect on the process. Similar results were obtained with the trypan blue exclusion assay, and the expression of wild-type JTB inhibited the cell death to 30% of the control. The expression levels of the wild-type and mutant JTB were comparable (Figure 6b ). On the other hand, the knockdown of JTB by siRNA enhanced the apoptosis as shown in Figure 6c . Together, we concluded that JTB negatively regulated the apoptotic process that was activated by TGF-b1. The spontaneous apoptosis observed in a small fraction of the cells (4-9%) under normal culture conditions, however, was not influenced by the level of JTB (Figures 6a and c ; TGF-b (À)).
Subsequently, the activation of caspase-9 was investigated. The process has been established to be dependent on a mitochondrial function, the release of cytochrome c, and when the mitochondria-dependent apoptotic process is activated, the enzyme is cleaved to a 37-kDa form. As demonstrated in Figure 6d , TGF-b1 increased the amount of this cleaved form, and the expression of wild-type JTB inhibited the process. This result suggested that TGF-b1 induced the apoptosis at least in part through a mitochondria-dependent pathway and that JTB affected the pathway. This result was consistent with the idea that JTB has a potential role in the regulation of mitochondrial function through which it exerted its effect on the apoptosis induced by TGF-b1.
Discussion
We recently isolated JTB as a TGF-b1-inducible clone by differential screening. In this study, we characterized the JTB product, aiming at understanding its biological functions in cells. The previous work reported on the potential production of an abnormal form of JTB as a consequence of the jumping translocation in the case of leukemia and discussed the possibility that the resultant truncated and soluble form of JTB interferes with the interaction between a ligand and a receptor in the immune system, thereby masking cancer cells from a host's defense system and contributing to the neoplastic change of cells (Hatakeyama et al., 1999) . We found that JTB was normally processed at the N-terminus to release the end of a 1-kDa polypeptide and largely localized to mitochondria (Figures 2 and 3) . Of interest, the processing was required for the biological activity of JTB, although the precise meaning of the processing is unknown at this stage. Forced expression of the wild-type JTB depressed the membrane potential of mitochondria ) were subjected to Western blotting using the anti-Flag antibody. In the electrophoresis used here, the processed and unprocessed forms were not clearly separated, and the result showed almost equal expression levels of the wild-type and mutant JTB. (c) NMuMG cells were treated with 200 pmol siRNA against JTB for 48 h and then, BrdU incorporation was determined as in (a). Under the conditions, JTB expression was reduced to less than 50% of the control at the mRNA level. The significance of the differences was assessed by t-test. After infection, the cells were selected with G418 for 10 days, pooled and left untreated or else treated with 2 ng/ml TGF-b1 for 24 and 48 h. Apoptotic cells were evaluated with an APOPercentage kit by measuring the uptake of the dye into cells, which was dependent on the transfer of phosphatidylserine to the outside of the membrane in apoptotic cells as described in Materials and methods. The incorporated dye was released from the cells and measured with a calorimeter. The absorbance was shown after correction for the cell number in each sample. The population of nonviable cells evaluated by trypan blue exclusion was 4-9% in the normal culture and increased to around 15, 30 and 60% 24, 48 and 72 h after the treatment with TGF-b1, respectively. *The significance of the differences was assessed by t-test (P ¼ 0.007). (b) The expression of the wild-type (JTB) and mutant (mJTB) JTB in the cells that were infected with the retroviral expression vectors and selected with G418 as in (a) were examined by Western blotting using anti-JTB antibody. (c) NMuMG cells were transfected with 200 pmol siRNA against JTB or control siRNA and at 24 h post-transfection, left untreated or treated with 2 ng/ml TGF-b1. At 24, 48 and 72 h after the treatment, the apoptotic cells were evaluated as in (a). *The significance of the differences was assessed by t-test (Po0.0007). (d) NMuMG cells were treated with 2 ng/ml TGFb1 for 48 h and uncleaved (p47), and cleaved and activated caspase-9 (p37) were detected by Western blotting.
Characterization of JTB located in mitochondria T Kanome et al and cellular growth, and conferred resistance to apoptosis induced by TGF-b1 (Figures 4-6 ). The mutant of JTB existing only as the unprocessed form did not induce any of these changes. The finding that the unprocessed form defective in regulating the mitochondrial membrane potential was also unable to affect cellular growth and apoptosis implied that the effect of wild-type JTB on cellular growth and apoptosis was associated with its function in mitochondria. This idea was supported by the finding that the wild-type JTB affected the activation of caspase-9 that was dependent on mitochondrial function upon induction of apoptosis by TGF-b1 (Figure 6d ). Thus, it was probable that JTB has a role in regulating mitochondrial function through which it affects cellular growth and apoptosis, and contributes to tumorigenic processes. Mitochondria are primarily energy-generating systems, the final step of which is oxidative phosphorylation coupled with an electron transport chain, supplying ATP. Having a pivotal role in the bioenergetic process, mitochondria are also critical to signaling events, receiving and integrating dynamically a wide range of signaling molecules from calcium ion to protein kinases, receptors and transcription factors (Goldenthal and Marin-Garcia, 2004) . Although numerous studies have focused on the integral role of mitochondrial signaling cascades in apoptotic progression, mitochondrial signaling is prominently involved in proliferative pathways, nutrient sensing, inter-organellar communication and stress responses of cells (Goldenthal and Marin-Garcia, 2004) .
The involvement of mitochondria in tumorigenesis was suggested initially by Warburg (1956) on the basis of a shift in energy metabolism observed generally in cancer cells, that is, respiration-coupled oxidative metabolism is reduced and glycolysis is increased. Since then, morphological and functional changes of mitochondria in cancer cells have been described (Dang and Semenza, 1999) , and point mutations and deletions in mitochondrial DNA have been increasingly reported in a wide range of tumor cells (Petros et al., 2005) . Of note, recent progress in cancer research provided possible explanations for Warburg's effect (Kondoh et al., 2005; Matoba et al., 2006; Pelicano et al., 2006) . These recent findings support the idea that decrease in the activity of mitochondrial functions including the respiratory chain acts as a driving force conferring an advantage on tumorigenesis.
In contrast, in cells carrying defects in respiratory chain components arising from mtDNA mutations, it is believed that the deregulated activity of the respiratory chain generally leads to an abnormal increase in electron leakage and the subsequent formation of superoxide, and causes additional mutations of mitochondrial DNA and also of nuclear DNA (Staniek et al., 2002; McKenzie et al., 2004) . This vicious cycle most probably contributes to the genetic instability in cancer cells. Together with another role under hypoxic conditions as potential oxygen sensors, which regulates the activation of HIF-a, critically involved in angiogenesis, metastasis and glycolysis (reviewed by Kaelin, 2005), mitochondrial respiratory activity, whether it is deregulated or not, is required to promote neoplastic changes as a major source of ROS.
In conclusion, these observations suggest both a positive and a negative impact of mitochondrial activities on tumorigenesis, depending on the stage of cancer progression as well as the various cellular and environmental factors affecting the neoplastic transformation of cells.
The results of profiling the cancer array (Figure 1b ) suggested that a decrease in JTB expression favorably affected the neoplastic transformation of cells. Although detailed molecular functions of JTB in mitochondria remains unexplored, it is conceivable that deregulated JTB expression or aberrant JTB products affect mitochondrial functions coupled with the metabolic states of cells and/or production of superoxide, thereby contributing to neoplastic transformation. The growth suppressive role of JTB was supposed to have a negative impact on cellular transformation, whereas its role in apoptosis inducing resistance to the process is expected to have a positive impact. Considering the complexity of the contributions of mitochondria to tumorigenesis as discussed above, this apparent inconsistency of the expected effects of JTB on tumorigenesis is unable to be reconciled, and the overall effect is unpredictable at this stage. In this respect, it is noteworthy that retardation of cellular growth and acquisition of resistance to apoptosis were both commonly observed upon the inhibition of replication and transcription in mitochondria (unpublished data). Most recently, Pelicano et al. (2006) reported that defects in mitochondrial respiration caused resistance to apoptosis and retardation of cell growth simultaneously. Of note, they revealed that mitochondrial respiration defects activated Akt survival pathway, which contributed to the acquisition of the resistance to apoptosis but apparently unrelated to the growth retardation. The decrease in cell growth rate was likely owing to metabolic disadvantage (Pelicano et al., 2006) . This finding raises the interesting possibility that a primary role of JTB is to induce a dormant state in mitochondria-like defects in the respiration, with which both suppression of growth and resistance to apoptosis are coupled but through different signaling, and that the dormant state affects favorably tumorigenesis overall.
Additionally, the expression of JTB was upregulated by TGF-b1 (Figure 1a) , which became evident later than 24 h after the treatment with TGF-b1, and further was upregulated for another 24-48 h. Although along with apoptosis, growth inhibition and epithelial mesenchymal transition were induced by TGF-b1 in NMuMG cells, only apoptosis was influenced and suppressed by the expression of JTB (Figure 6 and data not shown). Together, JTB appeared to have a role as a negativefeedback machinery for the apoptotic process induced by TGF-b1 signaling. Although TGF-b has been shown to elicit apoptotic cell death in a variety of cell types, the biochemical mechanism responsible for mediating the apoptotic process is still poorly understood. Several proapoptotic events associated with mitochondria, such as the induction of oxidative stress, downregulation of Bcl-2 or Bcl-X1 expression and activation of caspase, have been implicated in TGF-b-dependent apoptosis (Chen and Chang, 1997; Saltzman et al., 1998; Perlman et al., 2001; Kim et al., 2004) . Recently, a mitochondrial septin, ARTS, was shown to be involved in apoptosis induced by TGF-b (Larisch et al., 2000) . Most recently, DAP-kinase was identified as an effector of TGF-bdependent apoptosis, acting upstream of mitochondrial proapoptotic events (Jang et al., 2002) . JTB might be another molecule controlling TGF-b death signaling through mitochondria. Its precise role should be addressed in further study.
Studies on mitochondrial function and molecules acting on mitochondria are becoming increasingly important. Not only for understanding the process of neoplastic transformation of cells but also for the development of a new cancer chemotherapy. Actually, many apoptosis-inducing molecules have been explored as potential chemotherapeutic drugs for cancer (Costantini et al., 2000; Debatin et al., 2002; Marchetti et al., 2002; Kroemer, 2003; Rotem et al., 2005) . Further study of JTB will hopefully contribute to the development of such new drugs.
Materials and methods
Reagents TGF-b1 was purchased from Genzyme/Techne (Minneapolis, MN, USA) and Wako Pure Chemical Industries, Ltd (Osaka, Japan), respectively.
Cell culture
MNuMG mouse mammary epithelial cells were purchased from the American Type Culture Collection (Manassas, VA, USA) and propagated in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 3.5 g/l glucose and 10 mg/ml insulin. COS7 and A549 cells were cultured in Dulbecco's modified MEM supplemented with 10% fetal bovine serum. C3H10T1/2 was maintained as described previously (Kim-Kaneyama et al., 2005) .
Isolation of JTB
Total RNA was extracted from NMuMG cells left untreated or treated with TGF-b1 (2 ng/ml) for 24 h by a conventional guanidium isothiocyanate/hot phenol method, and poly(A) þ RNA was purified with oligo(dT)30-latex (oligotex-dT30, Takara Shuzo, Kyoto, Japan). The first-and second-strand cDNA were synthesized using the purified poly(A) þ RNA as a template, and a subtracted cDNA library was constructed with a PCR-selected subtraction cDNA kit (Clontech Laboratories Inc., Palo Alto, CA, USA). After the transfection of Escherichia coli with the library, kanamycin-resistant colonies were replica-plated and screened with 32 P-labeled cDNA probes prepared from poly(A) þ RNA prepared from NMuMG cells left untreated or else treated with TGF-b1 (2 ng/ml) for 24 h. Candidate clones were further screened by repeating the same procedure twice, and a total of 26 independent clones, one of which contained the JTB coding region, were isolated that showed an elevated expression in TGF-b1-treated cells.
Cancer profiling array
The array (Clontech Laboratories, Pala Alto, CA, USA) was hybridized and processed according to the manufacturer's instructions. cDNA for the coding region of JTB was labeled with the Megaprime DNA labeling system (Amersham Pharmacia Biotech., Buckinghamshire, UK) and used as the JTB probe. As a control, ubiquitin cDNA supplied with the kit was similarly labeled and used.
Expression vectors
Using the isolated full-length clone as a template, the open reading frame of JTB was PCR-amplified using Pyrobest DNA polymerase (Takara Shuzoh Co., Kyoto, Japan) and inserted into an expression vector, pCG-N-BL (Shibanuma et al., 2003) for the HA-tagged version (HA-JTB) and pFLAG-CMV-5a (Eastman Kodak Company, New Haven, CT, USA) for the Flag-tagged version (FLAG-JTB). The PCR-amplified sequence was verified by sequencing. Mutations were introduced with a QuickChange Site-Directed Mutagenesis Kit (Stratagene Co., La Jolla, CA, USA) using mutated primers and HA-JTB as a template according to the manufacturer's instructions, and two types of mutants (mutants 1 and 2) ( Figure 2b ) were created. Mutant 2 was used as HA-mJTB and transferred to pFLAG-CMV-5a to generate the Flag-tagged version of the mutant (FLAG-mJTB).
Retrovirus expression vectors for the wild type (JTB/pMXs-IG, -IN) and for mutant 2 (mJTB/pMXs-IG, -IN) were generated based on the pMXs-IG vector kindly provided by Dr Kitamura, Institute of Medical Science, University of Tokyo (Kitamura et al., 2003) . The coding region of green fluorescent protein of pMXs-IG was replaced with a neomycin resistance gene in pMXs-IN. The cDNA of JTB was excised from FLAG-JTB and FLAG-mJTB and inserted into pMXs-IG and -IN.
Transfection with plasmids and siRNA, and retroviral infection Transient transfections with plasmids were carried out using a conventional calcium phosphate precipitation method or electroporation with a Cell Line Optimization Nucleofector Kit (Amaxa Biosystems, Koeln, Germany). Clonal stable transformants were isolated by the introduction of an expression vector together with one carrying the neomycin resistance gene followed by selection with G418 for 10 days, and the expression of an exogenously introduced gene was confirmed by Western blotting. Clones JH 3-8 and JF 1-7 were established from transfections with wild-type JTB expression vectors, HA-JTB and FLAG-JTB, respectively. pMXs-IG-based vectors were first introduced into PLAT-E cells (packaging cells) by transfection using a calcium phosphate precipitation method, and 24 h later, the culture medium was centrifuged at 3000 r.p.m. and used as a source of retrovirus. Viral infection was carried out by replacing the culture medium of NMuMG with the viral source and incubating for 24 h in the presence of 4 mg/ml polybrene. The same procedure was repeated twice with a 24-h interval. The infection efficiency was determined by monitoring EGFP expression under a fluorescence microscope, and more than 70% efficiency was guaranteed.
RNA corresponding to both strands of mouse JTB (257-275; the coding region numbering) was synthesized by Nippon Gene Co., Ltd (Toyama, Japan). The duplex siRNA (200 pmol) was transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction. The knockdown effect was confirmed by RT-PCR, and the expression of JTB was reduced to about 40% of the control at the mRNA level.
Western blotting and subcellular fractionation Cells were solubilized in lysis buffer, separated by SDSpolyacrylamide gel electrophoresis and Western blotted as described previously (Kim-Kaneyama et al., 2005) .
For subcellular fractionation, cells were washed with icecold phosphate-buffered saline (PBS), collected and resuspended in Fraction buffer (20 mM sucrose, 20 mM HEPES pH 7.5, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA and 10 mM triethanolamine) containing protease inhibitor mix (Sigma, St Louis, MO, USA). Subsequently, the cell suspension was subjected to nitrogen cavitation (150 psi, 15 min) and centrifuged at 450 Â g for 2 min to remove nuclei and unbroken cells (fraction P1). The supernatant (fraction S1) was then centrifuged at 1000 g for 25 min to obtain the mitochondrial fraction (fraction M), and the post-mitochondrial supernatant (fraction S2) was centrifuged at 100 000 g for 60 min and separated into microsomal (fraction E) and cytoplasmic (fraction C) fractions. The proteins in each fraction were solubilized with lysis buffer and analysed by Western blotting after their concentration was determined using a BCA protein assay (PIERCE).
Antibodies and preparation of anti-JTB antibody
The primary antibodies used for Western blotting and immunocytochemistry were anti-HA polyclonal (Y-11, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-FLAG monoclonal M2 and polyclonal (Sigma), anti-calnexin polyclonal (Stressgen Biotechnologies, San Diego, CA, USA), antiOxphos complex III core 1 subunit monoclonal (Moleculer Probes Inc., Eugene, OR, USA), caspase-9 antibody (Cell Signaling Technology, Beverly, MA, USA), and anti-JTB polyclonal prepared as below.
The oligo peptide corresponding to the C terminus of JTB (amino acid 126-146, RQRQLDRKALEKVRKQIESI) was synthesized and conjugated to KLH. New Zealand white rabbits were immunized with an antigen with Freund's complete adjuvant. The serum was purified by affinity chromatography on an antigen-conjugated Sepharose 4B column.
Immunocytochemistry
Cells cultured on cover slips were fixed with 3.7% formalin/ PBS and processed as described previously (Shibanuma et al., 2003) . To stain mitochondria, cells were incubated with 0.5 mM Mito Tracker Red CM-H2XROS (Molecular probes) for 45 min, followed by fixation with 3.7% formalin/PBS and processed for immunostaining.
Fluorescence microscopy was carried out using an Axioskope microscope (Carl Zeiss) equipped with a high-speed cooled digital CCD camera fluorescence imaging system (ARGUS HiSCA, Hamamatsu Photonics, Hamamatsu, Japan).
Mitochondrial membrane potential
The mitochondrial membrane potential, DC m was estimated using 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazole carbocyanine chloride (JC-1, BioVision Research Products, Mountain View, CA, USA). Cells were incubated with 10 mM JC-1 in conditioned medium for 15 min at 371C and washed with Hank's balanced salt solution, and then emission at 585 nm was observed using a Nikon ECLIPSE TE2000-U microscope equipped with a high-speed cooled digital CCD camera (Nikon Corporation, Tokyo, Japan). Images were acquired with an AquaCosmos image acquisition and analysis system (Hamamatsu Photonics, KK Hamamatsu, Japan).
Electron microscopy Cells were washed with PBS and then sequentially fixed in 2.5% glutaraldehyde containing 0.1 M phosphate buffer (PB) for 30 min and in 1% osmium tetraoxide containing 3% potassium ferocyanate for 60 min at 41C. After stepwise dehydration in ethanol from 50 to 100% with 10% increments, cells were embedded in TABB EPON 812 resin kit with DMP30 (TAAB Laboratories Equipment Ltd, Berkshire, UK). Thin sections were treated with 2% uranium for 15 min, and then with 2% lead sulfate for 10 min and were observed with an electron microscope (1200EX II, Japan Electronics, Co., Tokyo, Japan).
Cell growth and death
Cell growth and death were examined using cell populations with 60-80 and 100% confluency, respectively.
BrdU incorporation was evaluated by immunocytochemistry with a cell proliferation kit (Amersham Biosciences, Piscataway, NJ, USA) according to the manufacturer's instructions.
Apoptotic cell death was evaluated with an APOPercentage kit (Biocolor Ltd, Newtonabbey, Northern Ireland) according to the manufacturer's directions. In this assay, the transfer of phosphatidylserine to the outside of the membrane, which occurs in apoptotic cells, permits the unidirectional transport of the APOPercentage dye into the cells, leading to the accumulation of the dye within the cells. The intracellular dye was then released into solution, and the concentration was measured using a microplate colorimeter.
Real-time RT-PCR
Total RNA (1 mg) extracted from cells was reverse-transcribed, amplified and analysed as described previously (Mori et al., 2004) . The PCR primers for JTB were designed using PrimerExpress 1.0 (Applied Biosynthesis, Foster City, CA, USA).
